Phylogica : 600% Effective

Always good to get a pearl out of Phylogica (ASX : PYC) informing us that their latest “petri dish” experiment works 600% better than a previous “petri dish” experiment. Also nice to see approximately 600% abuse of ASX continuous disclosure rules… Instead of writing yet another rant about PYC’s rubbish in vitro studies, I am going to…

A big idea for Phylogica…

Hands down, Phylogica (ASX : PYC) is one of the most wasteful, pointless and irrelevant ASX-listed biotech companies. I have previously written about this utter farce of a company and frankly speaking, I had nothing to add to the discussion when PYC announced their successful fundraising last week of ~$10m smackeroos. I had nothing positive…

The 2000 Mile Rule

When I was a kid, my Dad and I drove across the Nullarbor Plain, from Adelaide to Perth. I will never forget the experience and it rests in my mind as one of the most visually spectacular stretches of road I have ever driven along. It also very much reinforced my perception of how remote and far-flung…

The Incest of ASX Biopharma

It’s pretty hard to beat the Brits when it comes to situational comedy. As a dual-Australian/Canadian national educated in the UK, I suppose I have an intrinsic affinity for that dry, offhand style of humour. A few years ago, I stumbled across a brilliant comedy skit that visually captures precisely the fundamental reason why ASX biopharma is…

Compensation Matters

I have alluded to my distaste for excessive executive and board compensation several times since I started this blog. For example, my opinion is generally known that Geoff Cumming at Anteo Diagnostics (ASX : ADO) is considerably overpaid relative to the performance of his company, particularly revenue growth. Compensation  is also a multi-faceted beast and so…

It’s just not Phylogical…

What a truly lousy company. Several regular Long Tail readers have gloatingly reminded me today how gentle I was the last time I wrote about Phylogica (ASX : PYC), many moons ago. I guess it was the early days of The Long Tail and I was still trying to find hope in the world of ASX-listed biotech. After having read…

NRT, ANP, PYC, ACL, OBJ : A Week in Contrast

Last week was a pretty exciting week in Australian life sciences. Quite a bit happened, in fact I struggled to stay on top of it while being on vacation. We’ve seen a couple of good things happen, like PharmAxis, Sirtex recovery, etc. that are real bright spots on the Aussie biotech landscape. We’ve seen some…